|
1
|
Mohamed A, Krajewski K, Cakar B and Ma CX:
Targeted therapy for breast cancer. Am J Pathol. 183:1096–1112.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morris GJ, Naidu S, Topham AK, Guiles F,
Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, et al:
Differences in breast carcinoma characteristics in newly diagnosed
African-American and Caucasian patients: A single-institution
compilation compared with the National Cancer Institute's
Surveillance, Epidemiology, and End Results database. Cancer.
110:876–884. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Podo F, Buydens LM, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al FEMME Consortium: Triple-negative breast cancer:
Present challenges and new perspectives. Mol Oncol. 4:209–229.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lehmann BD and Pietenpol JA:
Identification and use of biomarkers in treatment strategies for
triple-negative breast cancer subtypes. J Pathol. 232:142–150.
2014. View Article : Google Scholar :
|
|
7
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kassam F, Enright K, Dent R, Dranitsaris
G, Myers J, Flynn C, Fralick M, Kumar R and Clemons M: Survival
outcomes for patients with metastatic triple-negative breast
cancer: Implications for clinical practice and trial design. Clin
Breast Cancer. 9:29–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Costa R, Shah AN, Santa-Maria CA, Cruz MR,
Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ
and Giles FJ: Targeting Epidermal Growth Factor Receptor in triple
negative breast cancer: New discoveries and practical insights for
drug development. Cancer Treat Rev. 53:111–119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eccles SA: The epidermal growth factor
receptor/Erb-B/HER family in normal and malignant breast biology.
Int J Dev Biol. 55:685–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wheeler DL, Dunn EF and Harari PM:
Understanding resistance to EGFR inhibitors-impact on future
treatment strategies. Nat Rev Clin Oncol. 7:493–507. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yarden Y and Pines G: The ERBB network: At
last, cancer therapy meets systems biology. Nat Rev Cancer.
12:553–563. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reis-Filho JS and Tutt AN: Triple negative
tumours: A critical review. Histopathology. 52:108–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livasy CA, Karaca G, Nanda R, Tretiakova
MS, Olopade OI, Moore DT and Perou CM: Phenotypic evaluation of the
basal-like subtype of invasive breast carcinoma. Mod Pathol.
19:264–271. 2006. View Article : Google Scholar
|
|
16
|
Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler
L, et al: Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakai K, Hung MC and Yamaguchi H: A
perspective on anti-EGFR therapies targeting triple-negative breast
cancer. Am J Cancer Res. 6:1609–1623. 2016.PubMed/NCBI
|
|
18
|
Reis-Filho JS, Milanezi F, Carvalho S,
Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM,
Lakhani SR, et al: Metaplastic breast carcinomas exhibit EGFR, but
not HER2, gene amplification and overexpression:
Immunohistochemical and chromogenic in situ hybridization analysis.
Breast Cancer Res. 7:R1028–R1035. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reis-Filho JS, Pinheiro C, Lambros MB,
Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S,
Mackay A, et al: EGFR amplification and lack of activating
mutations in metaplastic breast carcinomas. J Pathol. 209:445–453.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burness ML, Grushko TA and Olopade OI:
Epidermal growth factor receptor in triple-negative and basal-like
breast cancer: Promising clinical target or only a marker? Cancer
J. 16:23–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alvarez RH, Valero V and Hortobagyi GN:
Emerging targeted therapies for breast cancer. J Clin Oncol.
28:3366–3379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yi YW, Hong W, Kang HJ, Kim HJ, Zhao W,
Wang A, Seong YS and Bae I: Inhibition of the PI3K/AKT pathway
potentiates cytotoxicity of EGFR kinase inhibitors in
triple-negative breast cancer cells. J Cell Mol Med. 17:648–656.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin Q and Esteva FJ: Cross-talk between
the ErbB/HER family and the type I insulin-like growth factor
receptor signaling pathway in breast cancer. J Mammary Gland Biol
Neoplasia. 13:485–498. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Karamouzis MV, Konstantinopoulos PA and
Papavassiliou AG: Targeting MET as a strategy to overcome
crosstalk-related resistance to EGFR inhibitors. Lancet Oncol.
10:709–717. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nahta R, Yu D, Hung MC, Hortobagyi GN and
Esteva FJ: Mechanisms of disease: Understanding resistance to
HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol.
3:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamaguchi H, Chang SS, Hsu JL and Hung MC:
Signaling crosstalk in the resistance to HER family receptor
targeted therapy. Oncogene. 33:1073–1081. 2014. View Article : Google Scholar
|
|
29
|
Baselga J: Targeting tyrosine kinases in
cancer: The second wave. Science. 312:1175–1178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yi YW, You K, Bae EJ, Kwak SJ, Seong YS
and Bae I: Dual inhibition of EGFR and MET induces synthetic
lethality in triple-negative breast cancer cells through
downregulation of ribosomal protein S6. Int J Oncol. 47:122–132.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Massihnia D, Galvano A, Fanale D, Perez A,
Castiglia M, Incorvaia L, Listì A, Rizzo S, Cicero G, Bazan V, et
al: Triple negative breast cancer: Shedding light onto the role of
pi3k/akt/mtor pathway. Oncotarget. 7:60712–60722. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goldstein D, Bushmeyer SM, Witt PL, Jordan
VC and Borden EC: Effects of type I and II interferons on cultured
human breast cells: Interaction with estrogen receptors and with
tamoxifen. Cancer Res. 49:2698–2702. 1989.PubMed/NCBI
|
|
33
|
Duong HQ, You KS, Oh S, Kwak SJ and Seong
YS: Silencing of NRF2 reduces the expression of ALDH1A1 and ALDH3A1
and sensitizes to 5-FU in pancreatic cancer cells. Antioxidants.
6:62017. View Article : Google Scholar
|
|
34
|
Kim SI, Kim HJ, Lee HJ, Lee K, Hong D, Lim
H, Cho K, Jung N and Yi YW: Application of a non-hazardous vital
dye for cell counting with automated cell counters. Anal Biochem.
492:8–12. 2016. View Article : Google Scholar
|
|
35
|
Biscardi JS, Ishizawar RC, Silva CM and
Parsons SJ: Tyrosine kinase signalling in breast cancer: Epidermal
growth factor receptor and c-Src interactions in breast cancer.
Breast Cancer Res. 2:203–210. 2000. View
Article : Google Scholar
|
|
36
|
Finn RS, Dering J, Ginther C, Wilson CA,
Glaspy P, Tchekmedyian N and Slamon DJ: Dasatinib, an orally active
small molecule inhibitor of both the src and abl kinases,
selectively inhibits growth of basal-type/'triple-negative' breast
cancer cell lines growing in vitro. Breast Cancer Res Treat.
105:319–326. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Feder D and Bishop JM: Purification and
enzymatic characterization of pp60c-src from human platelets. J
Biol Chem. 265:8205–8211. 1990.PubMed/NCBI
|
|
38
|
Sekulić A, Hudson CC, Homme JL, Yin P,
Otterness DM, Karnitz LM and Abraham RT: A direct linkage between
the phosphoinositide 3-kinase-AKT signaling pathway and the
mammalian target of rapamycin in mitogen-stimulated and transformed
cells. Cancer Res. 60:3504–3513. 2000.
|
|
39
|
Kovacina KS, Park GY, Bae SS, Guzzetta AW,
Schaefer E, Birnbaum MJ and Roth RA: Identification of a
proline-rich Akt substrate as a 14-3-3 binding partner. J Biol
Chem. 278:10189–10194. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gingras AC, Gygi SP, Raught B, Polakiewicz
RD, Abraham RT, Hoekstra MF, Aebersold R and Sonenberg N:
Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism.
Genes Dev. 13:1422–1437. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Laplante M and Sabatini DM: mTOR signaling
at a glance. J Cell Sci. 122:3589–3594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sabatini DM: mTOR and cancer: Insights
into a complex relationship. Nat Rev Cancer. 6:729–734. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ueng SH, Chen SC, Chang YS, Hsueh S, Lin
YC, Chien HP, Lo YF, Shen SC and Hsueh C: Phosphorylated mTOR
expression correlates with poor outcome in early-stage triple
negative breast carcinomas. Int J Clin Exp Pathol. 5:806–813.
2012.PubMed/NCBI
|
|
46
|
Walsh S, Flanagan L, Quinn C, Evoy D,
McDermott EW, Pierce A and Duffy MJ: mTOR in breast cancer:
Differential expression in triple-negative and non-triple-negative
tumors. Breast. 21:178–182. 2012. View Article : Google Scholar
|
|
47
|
Montero JC, Esparís-Ogando A, Re-Louhau
MF, Seoane S, Abad M, Calero R, Ocaña A and Pandiella A: Active
kinase profiling, genetic and pharmacological data define mTOR as
an important common target in triple-negative breast cancer.
Oncogene. 33:148–156. 2014. View Article : Google Scholar
|
|
48
|
Ellard SL, Clemons M, Gelmon KA, Norris B,
Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M,
et al: Randomized phase II study comparing two schedules of
everolimus in patients with recurrent/metastatic breast cancer:
NCIC Clinical Trials Group IND.163. J Clin Oncol. 27:4536–4541.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jovanović B, Mayer IA, Mayer EL, Abramson
VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver
TM, et al: A Randomized phase II neoadjuvant study of cisplatin,
paclitaxel with or without everolimus in patients with stage II/III
triple-negative breast cancer (TNBC): Responses and long-term
outcome correlated with increased frequency of DNA damage response
gene mutations, TNBC subtype, AR status, and Ki67. Clin Cancer Res.
23:4035–4045. 2017. View Article : Google Scholar
|
|
50
|
Gonzalez-Angulo AM, Akcakanat A, Liu S,
Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM,
Valero V, et al: Open-label randomized clinical trial of standard
neoadjuvant chemotherapy with paclitaxel followed by FEC versus the
combination of paclitaxel and everolimus followed by FEC in women
with triple receptor-negative breast cancer. Ann Oncol.
25:1122–1127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Oualla K, El-Zawahry HM, Arun B, Reuben
JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT and Fouad
TM: Novel therapeutic strategies in the treatment of
triple-negative breast cancer. Ther Adv Med Oncol. 9:493–511. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu T, Yacoub R, Taliaferro-Smith LD, Sun
SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A, et
al: Combinatorial effects of lapatinib and rapamycin in
triple-negative breast cancer cells. Mol Cancer Ther. 10:1460–1469.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Madden JM, Mueller KL, Bollig-Fischer A,
Stemmer P, Mattingly RR and Boerner JL: Abrogating phosphorylation
of eIF4B is required for EGFR and mTOR inhibitor synergy in
triple-negative breast cancer. Breast Cancer Res Treat.
147:283–293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim DH, Sarbassov DD, Ali SM, King JE,
Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: mTOR
interacts with raptor to form a nutrient-sensitive complex that
signals to the cell growth machinery. Cell. 110:163–175. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen B, Tan Z, Gao J, Wu W, Liu L, Jin W,
Cao Y, Zhao S, Zhang W, Qiu Z, et al: Hyperphosphorylation of
ribosomal protein S6 predicts unfavorable clinical survival in
non-small cell lung cancer. J Exp Clin Cancer Res. 34:1262015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Iwenofu OH, Lackman RD, Staddon AP,
Goodwin DG, Haupt HM and Brooks JS: Phospho-S6 ribosomal protein: A
potential new predictive sarcoma marker for targeted mTOR therapy.
Mod Pathol. 21:231–237. 2008. View Article : Google Scholar
|
|
57
|
Komori Y, Yada K, Ohta M, Uchida H,
Iwashita Y, Fukuzawa K, Kashima K, Yokoyama S, Inomata M and Kitano
S: Mammalian target of rapamycin signaling activation patterns in
pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci.
21:288–295. 2014. View Article : Google Scholar
|
|
58
|
Masuda M, Chen WY, Miyanaga A, Nakamura Y,
Kawasaki K, Sakuma T, Ono M, Chen CL, Honda K and Yamada T:
Alternative mammalian target of rapamycin (mTOR) signal activation
in sorafenib-resistant hepatocellular carcinoma cells revealed by
array-based pathway profiling. Mol Cell Proteomics. 13:1429–1438.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Knoll M, Macher-Goeppinger S, Kopitz J,
Duensing S, Pahernik S, Hohenfellner M, Schirmacher P and Roth W:
The ribosomal protein S6 in renal cell carcinoma: Functional
relevance and potential as biomarker. Oncotarget. 7:418–432. 2016.
View Article : Google Scholar :
|
|
60
|
Green TP, Fennell M, Whittaker R, Curwen
J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM,
Wilkinson RW, et al: Preclinical anticancer activity of the potent,
oral Src inhibitor AZD0530. Mol Oncol. 3:248–261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Maira SM, Stauffer F, Brueggen J, Furet P,
Schnell CC, Brachmann S, Chène P, De Pover A, Schoemaker K, et al:
Identification and characterization of NVP-BEZ235, a new orally
available dual phosphatidylinositol 3-kinase/mammalian target of
rapamycin inhibitor with potent in vivo antitumor activity. Mol
Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Toledo LI, Murga M, Zur R, Soria R,
Rodriguez A, Martinez S, Oyarzabal J, Pastor J, Bischoff JR and
Fernandez-Capetillo O: A cell-based screen identifies ATR
inhibitors with synthetic lethal properties for cancer-associated
mutations. Nat Struct Mol Biol. 18:721–727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
O'Hare T, Walters DK, Stoffregen EP, Jia
T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC,
Deininger MW, et al: In vitro activity of Bcr-Abl inhibitors AMN107
and BMS-354825 against clinically relevant imatinib-resistant Abl
kinase domain mutants. Cancer Res. 65:4500–4505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Shah NP, Lee FY, Luo R, Jiang Y, Donker M
and Akin C: Dasatinib (BMS-354825) inhibits KITD816V, an
imatinib-resistant activating mutation that triggers neoplastic
growth in most patients with systemic mastocytosis. Blood.
108:286–291. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Rivera VM, Squillace RM, Miller D, Berk L,
Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F,
et al: Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor,
has broad antitumor activity and can be optimally administered
using intermittent dosing regimens. Mol Cancer Ther. 10:1059–1071.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chun KH, Kosmeder JW II, Sun S, Pezzuto
JM, Lotan R, Hong WK and Lee HY: Effects of deguelin on the
phosphatidylinositol 3-kinase/Akt pathway and apoptosis in
premalignant human bronchial epithelial cells. J Natl Cancer Inst.
95:291–302. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Schuler W, Sedrani R, Cottens S, Häberlin
B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG and Schreier MH: SDZ
RAD, a new rapamycin derivative: Pharmacological properties in
vitro and in vivo. Transplantation. 64:36–42. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Flanagan WM, Corthésy B, Bram RJ and
Crabtree GR: Nuclear association of a T-cell transcription factor
blocked by FK-506 and cyclosporin A. Nature. 352:803–807. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Folkes AJ, Ahmadi K, Alderton WK, Alix S,
Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA,
et al: The identification of
2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine
(GDC-0941) as a potent, selective, orally bioavailable inhibitor of
class I PI3 kinase for the treatment of cancer. J Med Chem.
51:5522–5532. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Carnero A: Novel inhibitors of the PI3K
family. Expert Opin Investig Drugs. 18:1265–1277. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Knight ZA, Gonzalez B, Feldman ME, Zunder
ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth
B, et al: A pharmacological map of the PI3-K family defines a role
for p110alpha in insulin signaling. Cell. 125:733–747. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
García-Martínez JM, Moran J, Clarke RG,
Gray A, Cosulich SC, Chresta CM and Alessi DR: Ku-0063794 is a
specific inhibitor of the mammalian target of rapamycin (mTOR).
Biochem J. 421:29–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Vlahos CJ, Matter WF, Hui KY and Brown RF:
A specific inhibitor of phosphatidylinositol 3-kinase,
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol
Chem. 269:5241–5248. 1994.PubMed/NCBI
|
|
74
|
Hirai H, Sootome H, Nakatsuru Y, Miyama K,
Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al:
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy
by standard chemotherapeutic agents or molecular targeted drugs in
vitro and in vivo. Mol Cancer Ther. 9:1956–1967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gills JJ and Dennis PA: Perifosine: Update
on a novel Akt inhibitor. Curr Oncol Rep. 11:102–110. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Nghiem P, Pearson G and Langley RG:
Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting
calcineurin and treating atopic dermatitis. J Am Acad Dermatol.
46:228–241. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Edwards SR and Wandless TJ: The
rapamycin-binding domain of the protein kinase mammalian target of
rapamycin is a destabilizing domain. J Biol Chem. 282:13395–13401.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shor B, Zhang WG, Toral-Barza L, Lucas J,
Abraham RT, Gibbons JJ and Yu K: A new pharmacologic action of
CCI-779 involves FKBP12-independent inhibition of mTOR kinase
activity and profound repression of global protein synthesis.
Cancer Res. 68:2934–2943. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Marone R, Cmiljanovic V, Giese B and
Wymann MP: Targeting phosphoinositide 3-kinase: Moving towards
therapy. Biochim Biophys Acta. 1784:159–185. 2008. View Article : Google Scholar
|
|
80
|
Somwar R, Niu W, Kim DY, Sweeney G,
Randhawa VK, Huang C, Ramlal T and Klip A: Differential effects of
phosphatidylinositol 3-kinase inhibition on intracellular signals
regulating GLUT4 translocation and glucose transport. J Biol Chem.
276:46079–46087. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yu K, Toral-Barza L, Shi C, Zhang WG,
Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al:
Biochemical, cellular, and in vivo activity of novel
ATP-competitive and selective inhibitors of the mammalian target of
rapamycin. Cancer Res. 69:6232–6240. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yaguchi S, Fukui Y, Koshimizu I, Yoshimi
H, Matsuno T, Gouda H, Hirono S, Yamazaki K and Yamori T: Antitumor
activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
J Natl Cancer Inst. 98:545–556. 2006. View Article : Google Scholar : PubMed/NCBI
|
